Asian Transplantation Week 2023

Nov. 15(Wed)~18(Sat), 2023
Conrad Seoul, Korea

Submission No.: CS01-9261
Session : Concurrent Symposium 1 (Kidney/Pancreas)
Date & Time, Place : November 17 (Fri), 08:00-09:30, Room 3F-1
Session Title : Kidney allograft in multi-organ transplantation

How to manage kidney allograft in heart-kidney transplantation

Hye Young Woo
Seoul National University Hospital, Republic of Korea

Associated heart and kidney diseases frequently coexist. A substantial number of patients diagnosed with simultaneous heart and kidney disorders may eventually necessitate both heart and kidney transplants. The rising prevalence of dual organ transplants emphasizes the imperative of devising a comprehensive perioperative management protocol. The intricate interplay between cardiac and renal functions becomes especially pronounced in the cardiorenal syndrome. This complex relationship demands a nuanced understanding, especially in patients poised for dual organ transplantation. In the combined transplantation paradigm, the renal graft confronts potential hemodynamic shifts following heart transplantation. Post-transplant, the left ventricular cavity often appears diminished, attributable to edema in the left ventricular wall. The post-ischemic state of the newly transplanted heart results in diminished ventricular compliance and augmented filling pressures. Complete denervation of the heart nullifies the baroreceptor reflex, eliminating reflexive heart rate increases when hypovolemia or vasodilation induces a decline in systemic blood pressure. In the immediate aftermath of heart transplantation, a state of reduced cardiac output frequently necessitates the bolstering of vasoactive and inotropic agents. This diminished perfusion and hemodynamic volatility jeopardize the kidney graft, heightening the risk of suboptimal functional outcomes post-HKT. Expedited cardiac function recovery and efforts to taper pharmacologic hemodynamic support are pivotal for the newly transplanted kidney's prognosis. Achieving and sustaining the optimal functionality of both transplanted organs, the heart and kidney, during the perioperative phase requires meticulous precision in medical management. The success of simultaneous heart-kidney transplantation (SHKT) is contingent upon perioperative strategies centered predominantly on hemodynamic equilibrium and organ preservation. Paramount in this context is the judicious deployment of inotropes, like dobutamine or milrinone, which enhance myocardial contractility and subsequently, cardiac output. Maintaining robust cardiac output is essential for ensuring adequate organ perfusion and safeguarding the newly transplanted kidney from ischemic insults. In scenarios where systemic hypotension is imminent, vasopressors, such as norepinephrine or vasopressin, are indispensable. By effectively elevating systemic vascular resistance and mean arterial pressure, these agents ensure that vital organs receive optimal perfusion, which is crucial for the viability and functionality of the transplants. Fluid

management is of paramount importance during this period. Striking a balance between overhydration, which can strain the newly transplanted heart, and underhydration, which can undermine renal function, is crucial. Continuous monitoring of parameters like central venous pressure, urine output, and other hemodynamic markers often guides clinical decisions. Deciding between crystalloids and colloids for resuscitation, complemented by the strategic deployment of diuretics, is integral to this management. Additionally, rigorous monitoring and adjustment of electrolytes, including potassium, magnesium, and calcium, are essential, as deviations can profoundly impact myocardial contractility, rhythm, and renal functionality. Overall, the perioperative management of SHKT patients necessitates a multidisciplinary approach, mandating cohesive collaboration between cardiac and renal specialists. Every clinical decision profoundly influences the prognosis and long-term trajectories for these patients. The objective of induction therapy is to deliver potent immunosuppression during periods when the allograft rejection risk is elevated, while also facilitating a deferred commencement of nephrotoxic Calcineurin Inhibitors (CNIs). Prominent agents encompass poly-clonal anti-thymocyte antibodies, targeting human thymocytes, such as anti-thymocyte globulin or rabbit thymoglobulin. Although these agents might mitigate early rejection risks, they may simultaneously elevate susceptibility to infections. Another agent of note is the anti-interleukin-2 receptor antagonist, basiliximab. It's pertinent to acknowledge that prevailing research has yet to conclusively delineate the merits or detriments of induction immunosuppression in HT recipients. In the SHKT context, specific considerations about immunosuppression hinge on the nephrotoxic properties of CNIs. This extends to the selection of induction therapies and the maintenance of long-term immunosuppression. While practices may diverge across transplant centers, the HT team typically offers guidance on selecting and calibrating immunosuppression levels. Predominantly, SHKT recipients adhere to a regimen amalgamating a calcineurin inhibitor, mycophenolate, and prednisone. Recognizing the challenges and intricacies of managing kidney function during and post-simultaneous heart and kidney transplantation is paramount for optimizing patient outcomes. As the cohort undergoing this dual transplantation expands, refining management protocols will ascend in priority.